The 7 major polycythemia vera markets reached a value of US$ 17.1 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 68.5 Billion by 2034, exhibiting a growth rate (CAGR) of 16.67% during 2023-2034.
The polycythemia vera market has been comprehensively analyzed in this report titled "Polycythemia Vera Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycythemia vera is a rare, chronic blood disorder characterized by an overproduction of white blood cells (WBCs), red blood cells (RBCs), and platelets in the bone marrow. This condition can lead to an increase in blood volume and thickness, which can further cause a range of complications, including heart attack and brain stroke. The common indications of the ailment include itchiness, especially after a warm bath, a feeling of fullness, pain in the left upper abdomen, unusual bleeding from the nose or gums, painful swelling of the big toe, shortness of breath, numbness, tingling, or burning in the hands, feet, legs, or arms, etc. In some cases, individuals might also experience vague symptoms, such as fatigue, headache, dizziness, blurred vision, etc. The diagnosis of polycythemia vera typically requires a combination of clinical features, a detailed medical history, and a physical exam. Numerous blood tests involving the measurement of hematocrit, iron-rich protein, platelets, etc., are further utilized to confirm a diagnosis. Additionally, the healthcare provider may perform bone marrow aspiration or biopsy to assess the bone marrow and its functioning.
The increasing cases of gene mutations that affect the development of blood cells in the bone marrow are primarily driving the polycythemia vera market. In addition to this, the rising prevalence of several associated risk factors, including advancing age, obesity, a history of blood clots, smoking, diabetes, pregnancy, etc., are also bolstering the market growth. Furthermore, the escalating adoption of effective medications, such as anti-platelets, antihistamines, selective serotonin reuptake inhibitors, etc., which provide symptom relief and boost the overall health of patients, is acting as another significant growth-inducing factor. Additionally, numerous key players are focusing on the better understanding of cellular pathways and gene mutations involved in the pathogenesis of polycythemia vera to launch more effective treatment alternatives. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of ropeginterferon alfa-2b, since it helps the immune system fight against the overactive bone marrow cells associated with the disease, thereby preventing the overproduction of red blood cells, is expected to drive the polycythemia vera market in the coming years.
This report provides an exhaustive analysis of the polycythemia vera market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycythemia vera and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycythemia vera market in any manner.
The polycythemia vera market has been comprehensively analyzed in this report titled "Polycythemia Vera Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycythemia vera is a rare, chronic blood disorder characterized by an overproduction of white blood cells (WBCs), red blood cells (RBCs), and platelets in the bone marrow. This condition can lead to an increase in blood volume and thickness, which can further cause a range of complications, including heart attack and brain stroke. The common indications of the ailment include itchiness, especially after a warm bath, a feeling of fullness, pain in the left upper abdomen, unusual bleeding from the nose or gums, painful swelling of the big toe, shortness of breath, numbness, tingling, or burning in the hands, feet, legs, or arms, etc. In some cases, individuals might also experience vague symptoms, such as fatigue, headache, dizziness, blurred vision, etc. The diagnosis of polycythemia vera typically requires a combination of clinical features, a detailed medical history, and a physical exam. Numerous blood tests involving the measurement of hematocrit, iron-rich protein, platelets, etc., are further utilized to confirm a diagnosis. Additionally, the healthcare provider may perform bone marrow aspiration or biopsy to assess the bone marrow and its functioning.
The increasing cases of gene mutations that affect the development of blood cells in the bone marrow are primarily driving the polycythemia vera market. In addition to this, the rising prevalence of several associated risk factors, including advancing age, obesity, a history of blood clots, smoking, diabetes, pregnancy, etc., are also bolstering the market growth. Furthermore, the escalating adoption of effective medications, such as anti-platelets, antihistamines, selective serotonin reuptake inhibitors, etc., which provide symptom relief and boost the overall health of patients, is acting as another significant growth-inducing factor. Additionally, numerous key players are focusing on the better understanding of cellular pathways and gene mutations involved in the pathogenesis of polycythemia vera to launch more effective treatment alternatives. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of ropeginterferon alfa-2b, since it helps the immune system fight against the overactive bone marrow cells associated with the disease, thereby preventing the overproduction of red blood cells, is expected to drive the polycythemia vera market in the coming years.
This report provides an exhaustive analysis of the polycythemia vera market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycythemia vera and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycythemia vera market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the polycythemia vera market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the polycythemia vera market
Competitive Landscape:
This report also provides a detailed analysis of the current polycythemia vera marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the polycythemia vera market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the polycythemia vera market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the polycythemia vera market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of polycythemia vera across the seven major markets?
- What is the number of prevalent cases (2018-2034) of polycythemia vera by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of polycythemia vera by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with polycythemia vera across the seven major markets?
- What is the size of the polycythemia vera patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of polycythemia vera?
- What will be the growth rate of patients across the seven major markets?
Polycythemia Vera: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for polycythemia vera drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycythemia vera market?
- What are the key regulatory events related to the polycythemia vera market?
- What is the structure of clinical trial landscape by status related to the polycythemia vera market?
- What is the structure of clinical trial landscape by phase related to the polycythemia vera market?
- What is the structure of clinical trial landscape by route of administration related to the polycythemia vera market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Polycythemia Vera - Unmet Needs10 Polycythemia Vera - Key Endpoints of Treatment13. Polycythemia Vera - Attribute Analysis of Key Marketed and Pipeline Drugs16 Polycythemia Vera - Recent Events and Inputs From Key Opinion Leaders18 Polycythemia Vera Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Polycythemia Vera - Introduction
5 Polycythemia Vera - Disease Overview
7 Polycythemia Vera - Epidemiology and Patient Population
8 Polycythemia Vera - Treatment Algorithm, Guidelines, and Medical Practices
11 Polycythemia Vera - Marketed Products
12 Polycythemia Vera - Pipeline Drugs
14. Polycythemia Vera - Clinical Trial Landscape
15 Polycythemia Vera - Market Scenario
17 Polycythemia Vera Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 133 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 17.1 Billion |
| Forecasted Market Value ( USD | $ 68.5 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
